FOLH1 and prostate carcinoma: Radioligand therapy using α- or β-emitting isotopes appears tempting, in light of recent break through clinical studies of theranostic agents targeting somatostatin receptors in neuroendocrine tumors [11] and prostate-specific membrane antigen (PSMA) in prostate cancer [12].